Risk prediction in MDS: independent validation of the IPSS-M-ready for routine?
Leukemia
.
2023 Apr;37(4):938-941.
doi: 10.1038/s41375-023-01831-1.
Epub 2023 Feb 1.
Authors
Constance Baer
#
1
,
Sandra Huber
#
2
,
Stephan Hutter
2
,
Manja Meggendorfer
2
,
Niroshan Nadarajah
2
,
Wencke Walter
2
,
Uwe Platzbecker
3
,
Katharina S Götze
4
,
Wolfgang Kern
2
,
Torsten Haferlach
2
,
Gregor Hoermann
2
,
Claudia Haferlach
2
Affiliations
1
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany. constance.baer@mll.com.
2
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.
3
Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University of Leipzig, Leipzig, Germany.
4
Technical University of Munich (TUM), School of Medicine, Department of Internal Medicine III, Munich, Germany.
#
Contributed equally.
PMID:
36725896
PMCID:
PMC10079546
DOI:
10.1038/s41375-023-01831-1
No abstract available
MeSH terms
Humans
Myelodysplastic Syndromes* / diagnosis
Myelodysplastic Syndromes* / genetics
Prognosis
Risk Factors